Chronic Granulomatous Disease Mimicking Colonic Crohn's Disease Successfully Treated with Infliximab
Author(s) -
Armando Peixoto,
Rosa Coelho,
Tiago Maia,
António Sarmento,
Fernando Magro,
Guilherme Macedo
Publication year - 2017
Publication title -
acg case reports journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 4
ISSN - 2326-3253
DOI - 10.14309/crj.2017.46
Subject(s) - chronic granulomatous disease , medicine , infliximab , crohn's disease , disease , immunology , granuloma , diarrhea , nadph oxidase , granulomatous disease , inflammatory bowel disease , gastroenterology , oxidative stress
Chronic granulomatous disease (CGD) is a genetically induced disease caused by mutations in one of the components of the NADPH-oxidase in phagocytes, characterized by life-threatening bacterial and fungal infections and granuloma formation. Treatment includes prevention of infectious complications and immunomodulation. However, a standard strategy is not yet defined. The authors report an X-linked CGD female carrier who presented during adulthood with diarrhea and colorectal ulcers, with high impairment of quality of life. Induction with infliximab 5 mg/kg (weeks 0, 2, and 6) with infectious prophylaxis was initiated. She continued infliximab 5 mg/kg every 8 weeks with complete symptomatic response at 15 months.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom